RNTCP and tuberculosis control - High time to act.
作者信息
Jain Nirmal Kumar
机构信息
Department of Chest Diseases and TB, SMS Medical College, Jaipur, India. E-mail:
出版信息
Lung India. 2010 Jul;27(3):108-10. doi: 10.4103/0970-2113.68303.
Abstract
摘要
相似文献
1
RNTCP and tuberculosis control - High time to act.
Lung India. 2010 Jul;27(3):108-10. doi: 10.4103/0970-2113.68303.
2
Utilization of and barriers to public sector tuberculosis services in India.
Natl Med J India. 2004 Nov-Dec;17(6):292-9.
3
Patients pathways to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study from a south Indian district.
BMC Public Health. 2017 Aug 4;17(1):635. doi: 10.1186/s12889-017-4627-7.
4
'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
Indian J Tuberc. 2020 Jan;67(1):20-28. doi: 10.1016/j.ijtb.2020.01.003. Epub 2020 Jan 15.
5
Challenges for the RNTCP in India.
J Indian Med Assoc. 2003 Mar;101(3):152-3.
6
Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients.
Int J Tuberc Lung Dis. 2009 Jun;13(6):698-704.
7
Impact of involvement of non-formal health providers on TB case notification among migrant slum-dwelling populations in Odisha, India.
PLoS One. 2018 May 23;13(5):e0196067. doi: 10.1371/journal.pone.0196067. eCollection 2018.
8
Involvement of non-governmental organisations in the RNTCP.
J Indian Med Assoc. 2003 Mar;101(3):167-8, 170.
9
Prevalence of initial drug resistance to M. tuberculosis in new sputum positive RNTCP patients.
J Commun Dis. 2003 Jun;35(2):82-9.
10
Strategy to Increase Awareness and Involvement of Private Medical Practitioners in RNTCP in Taluka Rahata of District Ahmednagar.
J Clin Diagn Res. 2015 Feb;9(2):LC10-4. doi: 10.7860/JCDR/2015/10724.5523. Epub 2015 Feb 1.
引用本文的文献
1
Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Indian J Pharmacol. 2021 Mar-Apr;53(2):143-152. doi: 10.4103/ijp.ijp_901_20.
2
Head and Neck Tuberculosis: Scenario in a Tertiary Care Hospital of North Eastern India.
J Clin Diagn Res. 2016 Jan;10(1):MC04-7. doi: 10.7860/JCDR/2016/17171.7076. Epub 2016 Jan 1.
3
Ethics, human rights and programmatic management of drug-resistant tuberculosis.
Lung India. 2012 Jan;29(1):95-6. doi: 10.4103/0970-2113.92384.
本文引用的文献
1
Outcomes of category III and I in immunocompetent patients of tuberculous lymphadenopathy treated in revised national tuberculosis control programme.
Lung India. 2010 Jul;27(3):115-7. doi: 10.4103/0970-2113.68305.
2
Why do tuberculosis suspects bypass local services to attend tuberculosis sanatorium?
Lung India. 2010 Jul;27(3):111-4. doi: 10.4103/0970-2113.68304.
3
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.
PLoS Med. 2009 Sep;6(9):e1000146. doi: 10.1371/journal.pmed.1000146. Epub 2009 Sep 15.
4
Prevalence of multidrug resistant Mycobacterium tuberculosis in Lucknow, Uttar Pradesh.
Indian J Med Res. 2008 Sep;128(3):300-6.
5
Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation.
Int J Tuberc Lung Dis. 2008 Aug;12(8):869-77.
6
Long term efficacy of DOTS regimens for tuberculosis: systematic review.
BMJ. 2008 Mar 1;336(7642):484-7. doi: 10.1136/bmj.39463.640787.BE. Epub 2008 Feb 4.
7
Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India.
Int J Tuberc Lung Dis. 2005 May;9(5):556-61.
8
Drug resistance in tuberculosis in India.
Indian J Med Res. 2004 Oct;120(4):377-86.
9
Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
Int J Tuberc Lung Dis. 2004 Jan;8(1):52-8.
10
Treatment of tuberculosis.
MMWR Recomm Rep. 2003 Jun 20;52(RR-11):1-77.
Zotero 插件